MWNA
PASG icon

Marshall Wace North America’s Passage Bio PASG Stock Holding History

Marshall Wace North America’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$624K Sell
3,129
-3,208
-51% -$765K ﹤0.01% 1062
2021
Q2 		$1.68M Sell
6,337
-7,822
-55% -$2.42M 0.01% 860
2021
Q1 		$4.95M Buy
+14,159
New +$6.05M 0.02% 569
2020
Q3 		– Sell
-729
Closed -$399K – 1410
2020
Q2 		$399K Sell
729
-2,333
-76% -$1.05M ﹤0.01% 963
2020
Q1 		$965K Buy
+3,062
New +$958K 0.01% 614

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace North America's PASG Position: Q3 2021 in Review

Marshall Wace North America reduced its Passage Bio (PASG) stake by 51% in Q3 2021, selling an estimated $765K and leaving 3,129 shares worth $624K. The position accounts for ﹤0.01% of the portfolio, ranked #1062.

Marshall Wace North America first reported a position in PASG in Q1 2020 and has held it in 5 quarters since. The position peaked at $4.95M in Q1 2021. 101 funds tracked by Wall St. Rank hold PASG as of Q3 2021.

  • Marshall Wace North America held 3,129 shares of Passage Bio worth $624K as of Q3 2021.
  • Marshall Wace North America sold 3,208 Passage Bio shares in Q3 2021, an estimated $765K.
  • Passage Bio made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1062 holding.
  • Marshall Wace North America first reported a position in Passage Bio in Q1 2020 and has held it in 5 quarters since.
  • Marshall Wace North America's Passage Bio position peaked at $4.95M in Q1 2021.
  • 101 funds tracked by Wall St. Rank held Passage Bio as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.